CTI BioPharma Cash Flow Statement

Financials in millions ZAR. Fiscal year is March - February.

Millions ZAR. Fiscal year is Mar - Feb.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Feb '25 Feb 28, 2025	Feb '24 Feb 29, 2024	Feb '23 Feb 28, 2023	Feb '22 Feb 28, 2022
Net Income	303.31	1.17	-16.91	7.65
Depreciation & Amortization	32.13	9.64	0.24	0.08
Stock-Based Compensation	2.34	0.53	-	-
Other Operating Activities	-293.98	18.03	-0.91	0.9
Change in Accounts Receivable	-3.57	-20.54	-5.73	-0.01
Change in Inventory	-144.18	-99.95	-	-
Change in Accounts Payable	70.16	93.17	-1.63	1.62
Change in Other Net Operating Assets	11.3	3.2	-4.9	-
Operating Cash Flow	-22.48	5.24	-29.82	10.24
Capital Expenditures	-49.11	-50.64	-21.99	-0.02
Cash Acquisitions	2.88	-	-	-
Sale (Purchase) of Intangibles	-21.07	-	-	-
Other Investing Activities	-	-	0.12	-
Investing Cash Flow	-67.3	-50.64	-21.87	-0.02
Long-Term Debt Issued	74.56	38.89	66.25	-
Long-Term Debt Repaid	-0.26	-0.14	-0.13	-10.03
Net Debt Issued (Repaid)	74.3	38.75	66.13	-10.03
Issuance of Common Stock	35.24	-	3.35	-
Repurchase of Common Stock	-1.55	-	-	-
Financing Cash Flow	108	38.75	69.47	-10.03
Miscellaneous Cash Flow Adjustments	-	-	0	-
Net Cash Flow	18.21	-6.65	17.78	0.19
Free Cash Flow	-71.6	-45.4	-51.81	10.22
Free Cash Flow Margin	-22.55%	-41.30%	-1153.41%	-
Free Cash Flow Per Share	-0.35	-0.29	-0.37	0.07
Cash Interest Paid	40.56	8.91	6.46	-
Cash Income Tax Paid	-0.27	-	-	-
Levered Free Cash Flow	-211.41	-67	-36.82	-
Unlevered Free Cash Flow	-189.11	-58.89	-32.88	-
Change in Net Working Capital	153.7	33.97	1.26	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.